Is ABT a good stock to buy right now?

Based on our 6-factor quantitative model, ABBOTT LABORATORIES (ABT) receives a "Hold" rating with a composite score of 45.5/100. It is ranked #1,859 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 57/100, Momentum 29/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for ABT?

ABBOTT LABORATORIES (ABT) has a "Hold" rating and 3-star score. The composite score of 45.5 ranks it #1,859 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is ABT in?

ABBOTT LABORATORIES operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $177.90 billion. It is classified as a large-cap stock.

Does ABT pay a dividend?

Yes, ABT pays a dividend with a current yield of 1.74%. For every $1,000 invested, you would receive approximately $17.40 in annual dividend income.

What is ABT's P/E ratio?

ABT has a trailing P/E ratio of 27.67x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is ABT?

ABT's quality factor score is 50/100. Gross margin: 56.1%. ROE: 12.1% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is ABT valued compared to peers?

ABT's value factor score is 57/100 (higher = cheaper). Key multiples: P/E 27.7x, EV/EBITDA 22.0x. Valuation is roughly in line with peers.

What is ABT's debt level?

ABT's debt-to-equity ratio is 25%. Sector average: 32%. Low leverage suggests conservative financial management.

ABT has a beta of 0.23, meaning it is less volatile than the market. Stability score: 89/100.

Does ABT have high short interest?

ABT's short interest factor score is 28/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

ABT Stock Analysis: Hold (Score 45.5/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
ABT	-2.36%	-2.50%	-9.27%	-19.95%	-19.44%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-2.29%	-6.10%	-9.61%	-19.58%	-48.96%	-	-	-
Alpha vs Sector	-1.00%	-2.84%	-5.46%	-15.11%	-28.65%	-	-	-

Metric	ABT	Benchmark
P/E Ratio	27.7x	+17%
EV/EBITDA	22.0x	+247%
Price / Book	3.4x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
ABT ABBOTT LABORATORIES	46	50	57	29	27.7x	12.1%	56.1%	14.7%	9.6%	25.0x	$177.9B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.5%	0.6%
Operating Margin %	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.3%	0.2%	0.2%	0.3%	0.2%
Net Margin %	0.1%	0.1%	0.3%	0.1%	0.2%	0.2%	0.1%	0.1%	0.1%	0.0%	0.1%
FCF Margin %	-17.8%	-	-	-	-	-	16.5%	14.1%	16.0%	16.2%	10.0%
ROE %	0.1%	0.1%	0.3%	0.1%	0.2%	0.2%	0.1%	0.1%	0.1%	0.0%	0.1%
ROA %	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%
ROIC %	0.1%	9.7%	8.7%	9.6%	12.3%	12.3%	9.5%	7.9%	6.2%	2.5%	10.5%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.6%

0.5%

0.6%

Operating Margin %

0.2%

0.1%

EBITDA Margin %

0.2%

0.3%

0.2%

0.3%

0.2%

Net Margin %

0.1%

0.3%

0.1%

0.2%

0.1%

0.0%

0.1%

FCF Margin %

-17.8%

16.5%

14.1%

16.0%

16.2%

10.0%

ROE %

0.1%

0.3%

0.1%

0.2%

0.1%

0.0%

0.1%

ROA %

0.1%

0.2%

0.1%

0.0%

ROIC %

0.1%

9.7%

8.7%

9.6%

12.3%

9.5%

7.9%

6.2%

2.5%

10.5%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$43.5B	$44.3B	$42.0B	$40.1B	$43.7B	$43.1B	$34.6B	$31.9B	$30.6B	$27.4B	$20.9B	$20.4B
	—	$19.3B	$18.7B	$18.0B	$19.1B	$18.5B	—	—	—	—	—	—
	$24.4B	$25.0B	$23.2B	$22.1B	$24.5B	$24.5B	$19.6B	$18.7B	$17.9B	$15.0B	$11.8B	$11.7B
Gross Margin	56.1%	56.4%	55.4%	55.2%	56.1%	57.0%	56.6%	58.5%	58.5%	54.7%	56.4%	57.1%
	—	$12.3B	$11.7B	$10.9B	$11.2B	$11.3B	—	—	—	—	—	—
Research & Development	—	$2.9B	$2.8B	$2.7B	$2.9B	$2.7B	$2.4B	$2.4B	$2.3B	$2.3B	$1.4B	$1.4B
Depreciation	—	—	—	—	—	—	$3.3B	$3.0B	$3.3B	$3.9B	$1.5B	$1.5B
Total Operating Expenses	—	$17.0B	$16.4B	$15.7B	$16.1B	$16.1B	—	—	—	—	—	—
	$7.7B	$8.1B	$6.8B	$6.5B	$8.4B	$8.4B	$5.4B	$4.5B	$3.6B	$1.6B	$3.2B	$2.9B
EBIT	$7.7B	$8.1B	$6.8B	$6.5B	$8.4B	$8.4B	$5.4B	$4.5B	$3.6B	$1.6B	$3.2B	$2.9B
EBITDA	$8.6B	$8.1B	$6.8B	$6.5B	$8.4B	$8.4B	$8.8B	$7.7B	$7.1B	$6.9B	$3.3B	$4.7B
Operating Margin	17.6%	18.2%	16.3%	16.2%	19.2%	19.6%	15.5%	14.2%	11.9%	5.7%	14.5%	14.1%
EBITDA Margin	19.8%	18.2%	16.3%	16.2%	19.2%	19.6%	25.4%	24.2%	23.1%	25.4%	15.6%	23.1%
	—	—	—	$637M	$558M	$533M	$546M	$733M	$993M	$904M	$431M	$163M
	—	$8.5B	$7.0B	$6.7B	$8.3B	$8.2B	—	—	—	—	—	—
Income Tax Expense	—	$1.9B	-$6.4B	$941M	$1.4B	$1.1B	$497M	$390M	$539M	$1.9B	$350M	$577M
	$6.4B	$6.5B	$13.4B	$5.7B	$6.9B	$7.1B	$4.5B	$3.7B	$2.4B	$477M	$1.4B	$4.4B
Net Margin	14.7%	14.7%	31.9%	14.3%	15.9%	16.4%	13.0%	11.6%	7.7%	1.7%	6.7%	21.7%
	$3.73	$3.73	$7.67	$3.28	$3.94	$3.97	$2.52	$2.07	$1.34	$0.27	$0.94	$2.94
Diluted EPS	$3.73	$3.72	$7.64	$3.26	$3.91	$3.94	$2.52	$2.07	$1.34	$0.27	$0.94	$2.94
Weighted Avg Basic	—	1.7B	1.7B	1.7B	1.8B	1.8B	—	—	—	—	—	—
Weighted Avg Diluted	—	1.7B	1.7B	1.7B	1.8B	1.8B	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$43.5B

$44.3B

$42.0B

$40.1B

$43.7B

$43.1B

$34.6B

$31.9B

$30.6B

$27.4B

$20.9B

$20.4B

—

$19.3B

$18.7B

$18.0B

$19.1B

$18.5B

—

$24.4B

$25.0B

$23.2B

$22.1B

$24.5B

$19.6B

$18.7B

$17.9B

$15.0B

$11.8B

$11.7B

Gross Margin

56.1%

56.4%

55.4%

55.2%

56.1%

57.0%

56.6%

58.5%

54.7%

56.4%

57.1%

—

$12.3B

$11.7B

$10.9B

$11.2B

$11.3B

—

Research & Development

—

$2.9B

$2.8B

$2.7B

$2.9B

$2.7B

$2.4B

$2.3B

$1.4B

Depreciation

—

$3.3B

$3.0B

$3.3B

$3.9B

$1.5B

Total Operating Expenses

—

$17.0B

$16.4B

$15.7B

$16.1B

—

$7.7B

$8.1B

$6.8B

$6.5B

$8.4B

$5.4B

$4.5B

$3.6B

$1.6B

$3.2B

$2.9B

EBIT

$7.7B

$8.1B

$6.8B

$6.5B

$8.4B

$5.4B

$4.5B

$3.6B

$1.6B

$3.2B

$2.9B

EBITDA

$8.6B

$8.1B

$6.8B

$6.5B

$8.4B

$8.8B

$7.7B

$7.1B

$6.9B

$3.3B

$4.7B

Operating Margin

17.6%

18.2%

16.3%

16.2%

19.2%

19.6%

15.5%

14.2%

11.9%

5.7%

14.5%

14.1%

EBITDA Margin

19.8%

18.2%

16.3%

16.2%

19.2%

19.6%

25.4%

24.2%

23.1%

25.4%

15.6%

23.1%

—

$637M

$558M

$533M

$546M

$733M

$993M

$904M

$431M

$163M

—

$8.5B

$7.0B

$6.7B

$8.3B

$8.2B

—

Income Tax Expense

—

$1.9B

-$6.4B

$941M

$1.4B

$1.1B

$497M

$390M

$539M

$1.9B

$350M

$577M

$6.4B

$6.5B

$13.4B

$5.7B

$6.9B

$7.1B

$4.5B

$3.7B

$2.4B

$477M

$1.4B

$4.4B

Net Margin

14.7%

31.9%

14.3%

15.9%

16.4%

13.0%

11.6%

7.7%

1.7%

6.7%

21.7%

$3.73

$7.67

$3.28

$3.94

$3.97

$2.52

$2.07

$1.34

$0.27

$0.94

$2.94

Diluted EPS

$3.73

$3.72

$7.64

$3.26

$3.91

$3.94

$2.52

$2.07

$1.34

$0.27

$0.94

$2.94

Weighted Avg Basic

—

1.7B

1.8B

—

Weighted Avg Diluted

—

1.7B

1.8B

—

ABBOTT LABORATORIES (ABT) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does ABBOTT LABORATORIES Do?

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. ABBOTT LABORATORIES (ABT) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Robert B. Ford and employs approximately 115,000 people, headquartered in Green Oaks, Illinois. With a market capitalization of $177.9B, ABT is one of the prominent companies in the Healthcare sector.

ABBOTT LABORATORIES (ABT) Stock Rating — Hold (April 2026)

As of April 2026, ABBOTT LABORATORIES receives a Hold rating with a composite score of 45.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ABT ranks #1,859 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ABBOTT LABORATORIES ranks #190 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ABT Stock Price and 52-Week Range

ABBOTT LABORATORIES (ABT) currently trades at $100.30. The stock lost $2.42 (2.4%) in the most recent trading session. The 52-week high for ABT is $139.06, which means the stock is currently trading -27.9% from its annual peak. The 52-week low is $105.27, putting the stock -4.7% above its annual trough. Recent trading volume was 11.9M shares, indicating strong institutional interest and high liquidity.

Is ABT Overvalued or Undervalued? — Valuation Analysis

ABBOTT LABORATORIES (ABT) carries a value factor score of 57/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 27.67x, compared to the Healthcare sector average of 23.63x — a premium of 17%. The price-to-book ratio stands at 3.35x, versus the sector average of 2.75x. The price-to-sales ratio is 4.07x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ABT trades at 22.03x EV/EBITDA, versus 6.34x for the sector.

Overall, ABT's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

ABBOTT LABORATORIES Profitability — ROE, Margins, and Quality Score

ABBOTT LABORATORIES (ABT) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 12.1%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 7.4% versus the sector average of -33.1%.

On a margin basis, ABBOTT LABORATORIES reports gross margins of 56.1%, compared to 71.5% for the sector. The operating margin is 17.6% (sector: -66.1%). Net profit margin stands at 14.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 9.6% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

ABT Debt, Balance Sheet, and Financial Health

ABBOTT LABORATORIES has a debt-to-equity ratio of 25.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.58x, suggesting adequate working capital coverage. Total debt on the balance sheet is $12.93B. Cash and equivalents stand at $7.51B.

ABT has a beta of 0.23, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ABBOTT LABORATORIES is 89/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

ABBOTT LABORATORIES Revenue and Earnings History — Quarterly Trend

In TTM 2026, ABBOTT LABORATORIES reported revenue of $43.50B and earnings per share (EPS) of $3.73. Net income for the quarter was $6.39B. Gross margin was 56.1%. Operating income came in at $7.66B.

In FY 2025, ABBOTT LABORATORIES reported revenue of $44.33B and earnings per share (EPS) of $3.73. Net income for the quarter was $6.52B. Gross margin was 56.4%. Revenue grew 5.7% year-over-year compared to FY 2024. Operating income came in at $8.05B.

In Q3 2025, ABBOTT LABORATORIES reported revenue of $11.37B and earnings per share (EPS) of $0.94. Net income for the quarter was $1.64B. Gross margin was 55.4%. Revenue grew 6.9% year-over-year compared to Q3 2024. Operating income came in at $2.06B.

In Q2 2025, ABBOTT LABORATORIES reported revenue of $11.14B and earnings per share (EPS) of $1.02. Net income for the quarter was $1.78B. Gross margin was 56.4%. Revenue grew 7.4% year-over-year compared to Q2 2024. Operating income came in at $2.05B.

Over the past 8 quarters, ABBOTT LABORATORIES has demonstrated a growth trajectory, with revenue expanding from $10.38B to $43.50B. Investors analyzing ABT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ABT Dividend Yield and Income Analysis

ABBOTT LABORATORIES (ABT) currently pays a dividend yield of 1.7%. At this yield, a $10,000 investment in ABT stock would generate approximately $$174.00 in annual dividend income. The net margin of 14.7% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

ABT Momentum and Technical Analysis Profile

ABBOTT LABORATORIES (ABT) has a momentum factor score of 29/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 28/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ABT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ABBOTT LABORATORIES (ABT) ranks #190 out of 838 stocks based on the Blank Capital composite score. This places ABT in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ABT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ABT vs S&P 500 (SPY) comparison to assess how ABBOTT LABORATORIES stacks up against the broader market across all factor dimensions.

ABT Next Earnings Date

No upcoming earnings date has been announced for ABBOTT LABORATORIES (ABT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ABT? — Investment Thesis Summary

ABBOTT LABORATORIES presents a balanced picture with arguments on both sides. Momentum is weak at 29/100, a headwind for near-term performance. Low volatility (stability score 89/100) reduces downside risk.

In summary, ABBOTT LABORATORIES (ABT) earns a Hold rating with a composite score of 45.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ABT stock.

Related Resources for ABT Investors

Explore more research and tools: ABT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ABT head-to-head with peers: ABT vs AZN, ABT vs SLGL, ABT vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says

Is Abbott Laboratories (ABT) Appealing After Recent Share Price Pullback?

Jury awards total of $70 million in damages in case against Abbott over infant formula

Chicago jury awards millions to families after babies fall ill after consuming Abbott formula

IL jury awards millions after babies fall ill after consuming formula

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

ABBOTT LABORATORIES (ABT) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does ABBOTT LABORATORIES Do?

ABBOTT LABORATORIES (ABT) Stock Rating — Hold (April 2026)

ABT Stock Price and 52-Week Range

Is ABT Overvalued or Undervalued? — Valuation Analysis

ABBOTT LABORATORIES Profitability — ROE, Margins, and Quality Score

ABT Debt, Balance Sheet, and Financial Health

ABBOTT LABORATORIES Revenue and Earnings History — Quarterly Trend

ABT Dividend Yield and Income Analysis

ABT Momentum and Technical Analysis Profile

ABT vs Competitors — Healthcare Sector Ranking and Peer Comparison

ABT Next Earnings Date

Should You Buy ABT? — Investment Thesis Summary

Related Resources for ABT Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says

Is Abbott Laboratories (ABT) Appealing After Recent Share Price Pullback?

Jury awards total of $70 million in damages in case against Abbott over infant formula

Chicago jury awards millions to families after babies fall ill after consuming Abbott formula

IL jury awards millions after babies fall ill after consuming formula